Cirrhosis is an important cause of morbidity and mortality in people with chronic liver
disease worldwide. In 2019, cirrhosis was associated with 2.4% of global deaths. Owing to …

Over the last two decades, there have been tremendous advances in the non-invasive
diagnosis and risk stratification of chronic liver diseases (CLDs). Non-invasive approaches …

Background & Aims Fibrosis-4 (FIB-4) and the nonalcoholic fatty liver disease fibrosis score
(NFS) are the 2 most popular noninvasive blood-based serum tests proposed for …

Alcohol-related liver disease (ALD) is a major cause of liver-related death worldwide, yet
understanding of the three key pathological features of the disease—fibrosis, inflammation …

Background & Aims There is a need for accurate biomarkers of fibrosis for population
screening of alcohol-related and non-alcoholic fatty liver disease (ALD, NAFLD). We …

The prevalence of non-alcoholic fatty liver disease (NAFLD) is continually increasing due to
the global obesity epidemic. NAFLD comprises a systemic metabolic disease accompanied …

As morbidity and mortality related to potentially preventable liver diseases are on the rise
globally, early detection of liver fibrosis offers a window of opportunity to prevent disease …

Type 2 diabetes mellitus is often associated with cirrhosis as comorbidities, acute illness,
medications, and other conditions profoundly alter glucose metabolism. Both conditions are …

Background & Aims Detection of patients with early cirrhosis is of importance to prevent the
occurrence of complications and improve prognosis. The SEAL program aimed at evaluating …

Simple Summary Non-alcoholic fatty liver disease (NAFLD) is expected to become the
leading cause of hepatocellular carcinoma (HCC) in the near future. In this article, we review …